Spastic cerebral palsy (CP), despite the name, is not consistently identifiable by specific
brain lesions. CP animal models focus on risk factors for development of CP, yet few …

Background Skeletal muscle relaxants (SMRs) are widely used in treating musculoskeletal
conditions. All SMRs, with the exception of baclofen and tizanidine, are on the list of 2023 …

A systematic rational search for newly designed melatonin derivatives, was performed using
a computer-assisted protocol. A total of 116 derivatives were generated by adding functional …

Background: The role of GABA-B neurotransmission in addiction has recently received
increased attention, with clinical trials indicating that baclofen, a GABA-B receptor agonist …

Baclofen is used as a skeletal muscle relaxant for multiple sclerosis patients and pediatric
patients with cerebral palsy and is prescribed to pediatric patients at 0.3 to 1.0 mg/kg/dose …

Baclofen is often considered a first-line treatment option for spasticity management in
children. However, adverse effects, administration, and dosing can be barriers to …

Recent focus on improving the recognition of dystonia in cerebral palsy (DCP) has
highlighted the need for more effective treatments. Evidence supports improved functional …

Background Management of refractory spasticity symptoms remains a challenging task for
clinicians. Intrathecal baclofen (ITB) therapy has emerged as a promising option for treating …

Pediatric spinal cord injury and dysfunction (SCI/D) can result from atypical embryologic
development or be acquired as the result of trauma, infection, autoimmune conditions, and …

Баклофен-миорелаксант, представляющий собой бета-р-хлорфенильное производное
одного из тормозных медиаторов-ГАМК. При применении этого препарата возможно …